422 related articles for article (PubMed ID: 32363737)
1. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study.
Birkeland KI; Bodegard J; Eriksson JW; Norhammar A; Haller H; Linssen GCM; Banerjee A; Thuresson M; Okami S; Garal-Pantaler E; Overbeek J; Mamza JB; Zhang R; Yajima T; Komuro I; Kadowaki T
Diabetes Obes Metab; 2020 Sep; 22(9):1607-1618. PubMed ID: 32363737
[TBL] [Abstract][Full Text] [Related]
2. Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries.
Norhammar A; Bodegard J; Eriksson JW; Haller H; Linssen GCM; Banerjee A; Karasik A; Mamouris P; Tangri N; Taveira-Gomes T; Maggioni AP; Botana M; Thuresson M; Okami S; Yajima T; Kadowaki T; Birkeland KI;
Diabetes Obes Metab; 2022 Jul; 24(7):1277-1287. PubMed ID: 35322567
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular and renal diseases in type 2 diabetes patients: 5-year cumulative incidence of the first occurred manifestation and hospitalization cost: a cohort within the French SNDS nationwide claims database.
Blin P; Joubert M; Jourdain P; Zaoui P; Guiard E; Sakr D; Dureau-Pournin C; Bernard MA; Lassalle R; Thomas-Delecourt F; Bineau S; Moore N; Droz-Perroteau C
Cardiovasc Diabetol; 2024 Jan; 23(1):22. PubMed ID: 38195491
[TBL] [Abstract][Full Text] [Related]
4. Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.
Komuro I; Kadowaki T; Bodegård J; Thuresson M; Okami S; Yajima T
Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():19-27. PubMed ID: 33835641
[TBL] [Abstract][Full Text] [Related]
5. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.
Birkeland KI; Bodegard J; Banerjee A; Kim DJ; Norhammar A; Eriksson JW; Thuresson M; Okami S; Ha KH; Kossack N; Mamza JB; Zhang R; Yajima T; Komuro I; Kadowaki T
Diabetes Obes Metab; 2021 Jan; 23(1):75-85. PubMed ID: 32893440
[TBL] [Abstract][Full Text] [Related]
6. Lifetime risk of cardiovascular-renal disease in type 2 diabetes: a population-based study in 473,399 individuals.
Zhang R; Mamza JB; Morris T; Godfrey G; Asselbergs FW; Denaxas S; Hemingway H; Banerjee A
BMC Med; 2022 Feb; 20(1):63. PubMed ID: 35130878
[TBL] [Abstract][Full Text] [Related]
7. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
Diabetes Obes Metab; 2021 Oct; 23(10):2207-2214. PubMed ID: 33973690
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology and resource use in Spanish type 2 diabetes patients without previous cardiorenal disease: CaReMe Spain study summary.
Sicras-Mainar A; Sicras-Navarro A; Palacios B; Sequera M; Blanco J; Hormigo A; Manito N; Alcázar-Arroyo R; Botana-Lopez MA
Endocrinol Diabetes Nutr (Engl Ed); 2022; 69(7):509-519. PubMed ID: 36084988
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study.
Kristófi R; Bodegard J; Norhammar A; Thuresson M; Nathanson D; Nyström T; Birkeland KI; Eriksson JW
Diabetes Care; 2021 May; 44(5):1211-1218. PubMed ID: 33653822
[TBL] [Abstract][Full Text] [Related]
10. Chronic kidney disease begets heart failure and vice versa: temporal associations between heart failure events in relation to incident chronic kidney disease in type 2 diabetes.
Wu MZ; Teng TK; Tay WT; Ren QW; Tromp J; Ouwerkerk W; Chandramouli C; Huang JY; Chan YH; Teramoto K; Yu SY; Lawson C; Li HL; Tse YK; Li XL; Hung D; Tse HF; Lam CSP; Yiu KH
Diabetes Obes Metab; 2023 Mar; 25(3):707-715. PubMed ID: 36346045
[TBL] [Abstract][Full Text] [Related]
11. Type 2 Diabetes Mellitus and Impact of Heart Failure on Prognosis Compared to Other Cardiovascular Diseases: A Nationwide Study.
Zareini B; Blanche P; D'Souza M; Elmegaard Malik M; Nørgaard CH; Selmer C; Gislason G; Kristensen SL; Køber L; Torp-Pedersen C; Schou M; Lamberts M
Circ Cardiovasc Qual Outcomes; 2020 Jul; 13(7):e006260. PubMed ID: 32571092
[TBL] [Abstract][Full Text] [Related]
12. Patients with type 1 and type 2 diabetes hospitalized with COVID-19 in comparison with influenza: mortality and cardiorenal complications assessed by nationwide Swedish registry data.
Kristófi R; Bodegard J; Ritsinger V; Thuresson M; Nathanson D; Nyström T; Norhammar A; Eriksson JW
Cardiovasc Diabetol; 2022 Dec; 21(1):282. PubMed ID: 36522650
[TBL] [Abstract][Full Text] [Related]
13. Risk factors, outcomes and healthcare utilisation in individuals with multimorbidity including heart failure, chronic kidney disease and type 2 diabetes mellitus: a national electronic health record study.
Pasea L; Dashtban A; Mizani M; Bhuva A; Morris T; Mamza JB; Banerjee A
Open Heart; 2023 Sep; 10(2):. PubMed ID: 37758654
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular and renal disease manifestation and healthcare resource utilization in patients on first-line oral therapy for type 2 diabetes: A claims-based observational cohort study.
Olufade T; Jiang L; Israni R; Huang J; Gosmanov AR
Diabetes Obes Metab; 2021 Dec; 23(12):2741-2751. PubMed ID: 34405521
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of chronic kidney disease in the Netherlands and its cardiovascular and renal complications.
Vervloet MG; de Jong HJ; Pander J; Overbeek JA
BMC Nephrol; 2023 Nov; 24(1):337. PubMed ID: 37957561
[TBL] [Abstract][Full Text] [Related]
16. Impact of type 2 diabetes on life expectancy and role of kidney disease among inpatients with heart failure in Switzerland: an ambispective cohort study.
Salvador D; Bano A; Wehrli F; Gonzalez-Jaramillo V; Laimer M; Hunziker L; Muka T
Cardiovasc Diabetol; 2023 Jul; 22(1):174. PubMed ID: 37438747
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and incidence of cardiovascular and renal diseases in type 1 compared with type 2 diabetes: A nationwide French observational study of hospitalized patients.
Ducluzeau PH; Fauchier G; Herbert J; Semaan C; Halimi JM; Angoulvant D; Fauchier L
Diabetes Metab; 2023 May; 49(3):101429. PubMed ID: 36736892
[TBL] [Abstract][Full Text] [Related]
18. Associations of New-Onset Atrial Fibrillation With Risks of Cardiovascular Disease, Chronic Kidney Disease, and Mortality Among Patients With Type 2 Diabetes.
Geng T; Wang Y; Lu Q; Zhang YB; Chen JX; Zhou YF; Wan Z; Guo K; Yang K; Liu L; Liu G; Pan A
Diabetes Care; 2022 Oct; 45(10):2422-2429. PubMed ID: 35984477
[TBL] [Abstract][Full Text] [Related]
19. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.
Charytan DM; Solomon SD; Ivanovich P; Remuzzi G; Cooper ME; McGill JB; Parving HH; Parfrey P; Singh AK; Burdmann EA; Levey AS; Eckardt KU; McMurray JJV; Weinrauch LA; Liu J; Claggett B; Lewis EF; Pfeffer MA
Diabetes Obes Metab; 2019 May; 21(5):1199-1208. PubMed ID: 30672083
[TBL] [Abstract][Full Text] [Related]
20. Long-term impact of cardiorenal syndromes on major outcomes based on their chronology: a comprehensive French nationwide cohort study.
Halimi JM; de Fréminville JB; Gatault P; Bisson A; Gueguen J; Goin N; Sautenet B; Maisons V; Herbert J; Angoulvant D; Fauchier L
Nephrol Dial Transplant; 2022 Nov; 37(12):2386-2397. PubMed ID: 35438794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
